SMNRW — Semnur Pharmaceuticals, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1913577 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -4,576,000 | -4,576,000 | 1,969,000 | 103,000 | 27,295,000 |
| Dec 2025 | 0 | — | -6,158,000 | -6,158,000 | 1,346,000 | 20,000 | 22,096,000 |
| Sep 2025 | 0 | — | -152,594,000 | -152,594,000 | 774,000 | 85,000 | 15,367,000 |
| Mar 2025 | 0 | — | -665,000 | -665,000 | 7,513,000 | 7,000 | 50,962,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,542,000
Investing CF
—
Financing CF
$7,501,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-275,800,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-160,193,000
Pretax Income TTM
$-160,193,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -160,416,000 | -160,416,000 | 1,346,000 | 22,096,000 | — | -5,867,000 |
| Dec 2024 | 0 | -4,690,000 | -4,690,000 | 6,684,000 | 49,468,000 | — | -4,891,000 |
| Dec 2023 | 0 | -3,261,000 | -3,261,000 | 703,000 | 38,797,000 | — | -1,677,000 |
| Dec 2022 | 0 | -3,765,000 | -3,765,000 | 762,000 | 35,595,000 | — | -4,043,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $949.47B | $1064.74 | — |
| JNJ | JOHNSON & JOHNSON | $554.09B | $230.18 | — |
| ABBV | AbbVie Inc. | $376.54B | $213.12 | — |
| MRK | Merck & Co., Inc. | $295.69B | $119.72 | — |
| AZN | ASTRAZENECA PLC | $290.30B | $187.19 | — |
Recent Insider Activity
No insider activity indexed for this ticker.